Minerva Neurosciences Inc (NERV)
2.40
+0.04
(+1.70%)
USD |
NASDAQ |
May 01, 16:00
Minerva Neurosciences Net Income (Quarterly): -9.022M for Dec. 31, 2023
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -9.022M |
| September 30, 2023 | -7.820M |
| June 30, 2023 | -6.192M |
| March 31, 2023 | -6.970M |
| December 31, 2022 | -6.726M |
| September 30, 2022 | -6.900M |
| June 30, 2022 | -8.718M |
| March 31, 2022 | -9.764M |
| December 31, 2021 | -21.31M |
| September 30, 2021 | -9.205M |
| June 30, 2021 | -10.59M |
| March 31, 2021 | -8.805M |
| December 31, 2020 | -7.325M |
| September 30, 2020 | -8.113M |
| June 30, 2020 | 29.53M |
| March 31, 2020 | -12.15M |
| December 31, 2019 | -29.92M |
| September 30, 2019 | -13.96M |
| June 30, 2019 | -12.48M |
| March 31, 2019 | -15.83M |
| December 31, 2018 | -13.20M |
| September 30, 2018 | -12.02M |
| Date | Value |
|---|---|
| June 30, 2018 | -12.53M |
| March 31, 2018 | -12.42M |
| December 31, 2017 | 0.1621M |
| September 30, 2017 | -11.26M |
| June 30, 2017 | -9.780M |
| March 31, 2017 | -10.64M |
| December 31, 2016 | -9.404M |
| September 30, 2016 | -8.423M |
| June 30, 2016 | -5.214M |
| March 31, 2016 | -8.004M |
| December 31, 2015 | -8.439M |
| September 30, 2015 | -5.939M |
| June 30, 2015 | -6.610M |
| March 31, 2015 | -6.093M |
| December 31, 2014 | -7.442M |
| September 30, 2014 | -27.16M |
| June 30, 2014 | -19.37M |
| March 31, 2014 | -2.938M |
| December 31, 2013 | -2.126M |
| September 30, 2013 | -0.4882M |
| June 30, 2013 | -0.376M |
| March 31, 2013 | -0.2713M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-29.92M
Minimum
Dec 2019
29.53M
Maximum
Jun 2020
-8.760M
Average
-8.805M
Median
Mar 2021
Net Income (Quarterly) Benchmarks
| Viking Therapeutics Inc | -27.36M |
| Janux Therapeutics Inc | -11.76M |
| ACADIA Pharmaceuticals Inc | 45.80M |
| Karyopharm Therapeutics Inc | -41.84M |
| Calidi Biotherapeutics Inc | -8.229M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 7.172M |
| EPS Diluted (Quarterly) | -1.20 |
| Enterprise Value | -24.13M |
| Earnings Yield | -194.2% |